Noninferior Antibiotics: When Is “Not Bad” “Good Enough”?

Author:

DiNubile Mark J.1

Affiliation:

1. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, New Jersey

Abstract

Abstract Novel treatment options are urgently needed for patients with serious multidrug-resistant infections seen increasingly in routine everyday clinical practice, both in the hospital and nursing home as well as in the clinic and office setting. Unfortunately, the problem is no longer confined to chronically ill, repeatedly hospitalized patients. This essay explores the role of noninferiorly studies in addressing the pressing need for new antimicrobial agents to combat the emerging “superbugs”, calling attention to the nuances of interpreting their sometimes less-than-straightforward results. The overriding aim is not to find better antibiotics for routinely treatable infections but to identify safe and efficacious treatment options where none presently exist.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Reference25 articles.

1. The 10 × 20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020;Gilbert;Clin Infect Dis,2010

2. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments;Rex;Lancet Infect Dis,2013

3. Challenges of antibiotic discovery;Lewis;Microbe,2015

4. The crisis of no new antibiotics—what is the way forward?;Piddock;Lancet Infect Dis,2012

5. Antibiotic research and development: business as usual?;Harbarth;J Antimicrob Chemother,2015

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3